Skip to main content

Table 5 Association of HAART and other variables with dyslipidemia among HIV-infected patients

From: Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon

Explanatory Variables

TC ≥ 200 mg/dL AOR (95 % CI)

LDL-c ≥ 130 mg/dL AOR (95 % CI)

HDL-c < 40 mg/dL AOR (95 % CI)

TG ≥ 150 mg/dL AOR (95 % CI)

TC/HDL-c ≥ 5 AOR (95 % CI)

Antiretroviral therapy

     

 HAART-naïve*

1.00

1.00

1.00

1.00

1.00

 HAART treated

6.24 (2.33-17.45)

5.28 (1.17-16.32)

1.07 (0.37-3.05)

0.86 (0.32-2.28)

2.51 (0.64-9.89)

p-value

< 0.001

0.004

0.904

0.762

0.188

Gender

     

 Male*

1.00

1.00

1.00

1.00

1.00

 Female

2.17 (0.99-4.74)

1.20 (0.55-2.65)

0.45 (0.19-1.07)

0.44 (0.19-1.01)

0.42 (0.16-1.09)

p-value

0.053

0.645

0.071

0.054

0.076

Age group

     

  ≤ 40 years*

1.00

1.00

1.00

1.00

1.00

  > 40 years

1.11 (0.58-2.31)

0.91 (0.47-1.78)

0.80 (0.35-1.84)

1.22 (0.57-2.58)

1.02 (0.42-2.46)

 p-value

0.746

0.789

0.605

0.611

0.963

Body Mass Index

     

 BMI < 25 kg/m2*

1.00

1.00

1.00

1.00

1.00

 BMI ≥ 25 kg/m2

0.98 (0.52-1.86)

1.07 (0.56-2.05)

0.88 (0.39-1.98)

3.25 (1.44-7.34)

2.19 (0.87-5.51)

p-value

0.962

0.845

0.757

0.005

0.097

HIV duration

     

  < 42 months*

1.00

1.00

1.00

1.00

1.00

  ≥ 42 months

2.26 (1.16-4.42)

1.71 (0.85-3.45)

1.32 (0.53-3.29)

1.89 (0.81-4.41)

1.58 (0.60-4.13)

p-value

0.017

0.133

0.0.545

0.140

0.350

  1. TC-Total Cholesterol, LDL-c-Low-Density Lipoprotein Cholesterol, HDL-c-High-Density Lipoprotein Cholesterol, TG-Triglyceride; HAART-Highly Active Antiretroviral Therapy, AOR-Adjusted Odds Ratio, BMI-Body Mass Index; *-Reference category